STOCK TITAN

Vaxcyte, Inc. - PCVX STOCK NEWS

Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.

Vaxcyte, Inc. (Nasdaq: PCVX) is a pioneering biopharmaceutical company based in San Carlos, California, dedicated to developing high-fidelity vaccines to protect against serious bacterial infections. Vaxcyte aims to improve global health through innovative vaccines designed to prevent diseases that conventional options fail to address effectively.

The company's flagship product, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) designed to provide broad-spectrum protection against invasive pneumococcal disease (IPD). VAX-24 is engineered to cover more strains than the current leading vaccines, addressing a significant unmet need in both adult and pediatric populations. Vaxcyte's advanced cell-free protein synthesis platform, XpressCF™, is pivotal in developing these complex conjugate vaccines, allowing for efficient production and enhanced immunogenicity.

Vaxcyte's pipeline includes VAX-31, a next-generation 31-valent PCV, currently in Phase 1/2 clinical trials. VAX-31 aims to achieve the broadest coverage of any PCV to date, targeting 95% of IPD strains circulating in the U.S. adult population. Additionally, the company is developing other promising vaccine candidates such as VAX-A1 for Group A Strep infections, VAX-PG for periodontal disease, and VAX-GI for Shigella prevention.

Recent milestones include the successful completion of enrollment in the VAX-31 Phase 1/2 trial and the VAX-24 infant Phase 2 study. The FDA granted Breakthrough Therapy designation to VAX-24, reflecting its potential to offer substantial improvements over existing treatments. Vaxcyte is on track to advance VAX-24 into Phase 3 trials, with topline data anticipated by 2025.

Financially, Vaxcyte is robust, supported by $1.4 billion in recent follow-on equity financings to advance its vaccine candidates and expand its manufacturing capabilities.

For more information, visit www.vaxcyte.com.

Rhea-AI Summary

Vaxcyte has appointed John Furey to its Board of Directors, effective July 2, 2024. Furey brings extensive experience in the biopharmaceutical and vaccine sectors, especially in the manufacture, supply, and commercialization of pneumococcal conjugate vaccines (PCVs). This addition comes as Vaxcyte advances its PCV candidates, VAX-24 and VAX-31, towards late-stage clinical development. Furey's expertise is expected to provide strategic insights and strengthen the company’s efforts in developing innovative vaccines using a cell-free technology platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
management
-
Rhea-AI Summary

Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2024 financial results, highlighting completion of enrollment for VAX-31 Adult Phase 1/2 study and VAX-24 Infant Phase 2 study. They expect data by Q3 2024 and Q1 2025 respectively. The company had $1.9 billion in cash as of March 31, 2024, following a successful $816.5 million public offering in February. The company is progressing its PCV franchise and early-stage pipeline, focusing on preventing bacterial diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on high-fidelity vaccines for bacterial diseases. The webcast can be accessed on their website with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) completes enrollment in Phase 2 study for VAX-24, a 24-valent pneumococcal conjugate vaccine. Topline safety, tolerability, and immunogenicity data expected by Q1 2025, followed by booster dose data by end of 2025. VAX-24 aims to cover more serotypes than existing vaccines, addressing the need for broader-spectrum protection against IPD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) completes enrollment in VAX-31 Adult Program Phase 1/2 study and expects topline safety, tolerability, and immunogenicity data in Q3 2024. Successful completion of VAX-24 Phase 2 Adult Program, moving towards Phase 3 readiness. Progress in VAX-24 Infant Phase 2 Study with expected data by Q1 2025. Significant advancements in global commercial manufacturing capacity. The company holds $1.2 billion in cash and investments as of December 31, 2023, with recent net proceeds of $816.5 million. Vaxcyte aims to advance either VAX-24 or VAX-31 into Phase 3 adult clinical program post VAX-31 study readout.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) will report Q4 and full-year 2023 financial results on Feb 27, 2024. A conference call and webcast will follow to discuss results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences earnings
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) closed its underwritten public offering of common stock, generating approximately $862.5 million in gross proceeds. The offering included over 12.6 million shares of common stock and pre-funded warrants to purchase additional shares, with joint book-running managers and lead managers overseeing the process. The company filed a shelf registration statement with the SEC, and the final prospectus supplement and accompanying prospectus are available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on February 8, 2024. The live webcast can be accessed through the Investors & Media section of the Company’s website. A replay will be available for approximately 30 days after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
-
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expecting to generate approximately $750.0 million in gross proceeds. The offering includes 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock, with a public offering price of $64.00 per share for common stock and $63.999 per pre-funded warrant. The underwriters have been granted a 30-day option to purchase up to an additional 1,757,812 shares of common stock at the public offering price per share. The offering is expected to close on February 2, 2024, subject to customary closing conditions. BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering, with BTIG and Needham & Company as lead managers. Vaxcyte has filed a shelf registration statement with the SEC, and a preliminary prospectus supplement and accompanying prospectus have been filed. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) has initiated an underwritten public offering of its common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase additional shares. BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. The company filed a shelf registration statement with the SEC, and a preliminary prospectus supplement will be available on the SEC's website. This press release does not constitute an offer to sell or a solicitation to buy these securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags

FAQ

What is Vaxcyte, Inc.'s primary focus?

Vaxcyte is focused on developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

What are the key products in Vaxcyte's pipeline?

Vaxcyte's key products include VAX-24, a 24-valent pneumococcal conjugate vaccine, and VAX-31, a 31-valent PCV, along with other candidates like VAX-A1, VAX-PG, and VAX-GI.

What makes VAX-24 different from existing vaccines?

VAX-24 is designed to provide broader protection against more pneumococcal strains compared to current vaccines, addressing significant unmet needs in both adults and children.

What is the XpressCF™ platform?

XpressCF™ is Vaxcyte's cell-free protein synthesis platform that allows efficient production of complex vaccines with enhanced immunogenic benefits.

What recent milestones has Vaxcyte achieved?

Recent milestones include the completion of enrollment in the VAX-31 Phase 1/2 trial and the VAX-24 infant Phase 2 study, along with FDA Breakthrough Therapy designation for VAX-24.

When is Vaxcyte expected to release data from its VAX-24 Phase 3 trials?

Vaxcyte plans to release topline data from the VAX-24 Phase 3 trials by 2025.

What financial support does Vaxcyte have for its projects?

Vaxcyte is financially supported by recent equity financings totaling approximately $1.4 billion.

Where can I find more information about Vaxcyte?

For more information, you can visit Vaxcyte's official website at www.vaxcyte.com.

What is VAX-31 and its significance?

VAX-31 is a 31-valent pneumococcal conjugate vaccine aiming to cover 95% of invasive pneumococcal disease strains in the U.S. adult population, representing the broadest coverage in PCV candidates.

What other vaccine candidates is Vaxcyte developing?

Besides VAX-24 and VAX-31, Vaxcyte is developing VAX-A1 for Group A Strep, VAX-PG for periodontal disease, and VAX-GI for Shigella.

Vaxcyte, Inc.

Nasdaq:PCVX

PCVX Rankings

PCVX Stock Data

8.96B
108.80M
0.61%
112.17%
8.9%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN CARLOS